KDR and cancer: Therefore, targeting VEGF-A/VEGFR-2 or VEGF-C/VEGFR-3 signaling represents a promising strategy for the treatment of angiogenesis- or lymphangiogenesis-related diseases, particularly for intervention of cancer (7, 15).